Abstract 12133: Real-World Adherence to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States
Ahmad Masri, Ervant J Maksabedian Hernandez, Yan Wang, Weihua Gao, Aozhou Wu, Xu Han- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Background: There are no data on adherence to mavacamten in the real world. The first month of mavacamten treatment could be provided by the manufacturer for free before the drug is dispensed from commercial specialty pharmacies.
Research Question: What is the adherence to mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) in the real world?
Aims: To assess the adherence to mavacamten in real-world patients with obstructive HCM.
Methods: This was a retrospective cohort study of adult patients using the Symphony Integrated Dataverse that captured dispensing of commercial specialty pharmacies. Patients were included if they had ≥1 approved claim for mavacamten (the date of the first claim was the index date) from 4/28/2022 - 4/4/2023 and had continuous claims activity during the 12 months (baseline) before the index date. Discontinuation (defined as a gap ≥ 95 days in mavacamten treatment) and adherence (measured as proportion of days covered [PDC], modified medication possession ratio [MPRm], and compliance ratio [CR]) were evaluated during the follow-up that ended with the end of continuous claims activity or the end of the database, whichever was earlier. The use of background therapy was described at index. Subgroup analyses were conducted in patients with ≥2 approved mavacamten claims.
Results: A total of 659 patients (mean ± SD age 64.2 ± 13.1 years, 63.0% female) were included ( Table ). During an average of 118 ± 76 days follow-up, 4.1% of patients discontinued mavacamten who were on treatment for an average of 56 ± 44 days. The PDC (mean ± SD) was 95.6 ± 7.1%, with 94.7% of patients having a PDC ≥ 80%. Overall, 22.8% of patients received mavacamten as a monotherapy without any background therapies at index. The subgroup analysis showed similar results and a MPRm (mean ± SD) of 99.5 ± 11.8%.
Conclusion(s): Adherence to mavacamten over a mean of 118 days in the real world was high. Further follow-up is undergoing to understand adherence in a longer term.